HAE

Summary

Reduce existing HAE positions; do not initiate new longs at $104.04 and do not short. The stock is fundamentally strong (Q1 FY2027 beat, raised guidance, 25% plasma disposables growth, CSL Plasma deal, $312.8M TTM FCF, aggressive buybacks) but technically exhausted (RSI 83.10, price 6.5% above upper Bollinger Band, 14.7% above 10 EMA, +61% in 90 days). For existing holders, tighten stops below the breakout zone at $97–98 (not $95, given ATR 3.81 whipsaw risk). For new entry, wait for a pullback into $90–97 with confirmation (RSI cooling below 70, MACD histogram flattening, declining volume on the pullback). Size any new position at roughly half normal allocation given 114% implied volatility. Time horizon: 5 trading days for the alpha call; the next earnings catalyst is months away, so near-term direction is dominated by mean-reversion risk.

The case

At $104.04 over the next 5 trading days, the overbought condition and the absence of a near-term catalyst outweigh the still-intact uptrend, supporting an Underweight stance.

The bull case: forward P/E of 18.13x is reasonable for a 24% ROIC compounder with 25% plasma disposables growth; the trailing P/E of 50x is distorted by a one-time $77.2M impairment; the CSL Plasma deal is a multi-year recurring-revenue catalyst; OI ratio of 0.42 indicates the 4.31 put/call volume is short-term hedging rather than structural bearishness; $312.8M TTM FCF against $950M net debt is manageable; analyst targets are lagging and will likely revise to $115–120. These are legitimate points.

The bear case: RSI 83.10 and price 6.5% above the upper Bollinger Band are statistical outliers with historically >70% probability of mean reversion within 10 days; the stock trades ~5% above the $98.90 consensus target; the $300M revolver draw to settle convertibles signals cash-flow timing pressure; net debt exceeds equity (140% D/E); the next earnings catalyst is months away, leaving no scheduled event to justify current price. These are also legitimate points.

Where each side overreaches: the bull's "pullback already happened" and "contrarian bullish" spin on 4.31 put/call is a stretch, and dismissing the impairment as a "red herring" is too cavalier. The bear's "bubble in the making" and "SELL into strength" is hyperbolic given genuine fundamental quality. Both cherry-picked the same data.

The decisive factor for the 5-day horizon is the absence of a near-term catalyst combined with extreme overbought readings. The fundamental re-rating is real but multi-quarter; the next 5 days are dominated by mean-reversion risk against a still-intact uptrend. This produces a negative tilt — the overbought condition and lack of near-term catalyst outweigh the persistent trend strength — enough to justify an Underweight despite the confirmed uptrend and strong fundamentals. Our analysis cautions against over-weighting technicals when a fresh fundamental catalyst is present, but here no such catalyst is scheduled in the near term, so the overbought condition should be respected.

What would weaken it

• Extreme overbought readings (RSI 83.10, 6.5% above upper Bollinger Band) with >70% mean-reversion odds
• No near-term earnings catalyst; next catalyst months away
• Net debt exceeds equity (140% D/E) with $300M revolver draw signaling cash-flow timing pressure